Canadian Bioinformatics Workshops

Slides:



Advertisements
Similar presentations
Metabolomics and the Human Metabolome Project
Advertisements

1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.
Machine learning methods for the analysis of heterogeneous, multi- source data Ilkka Huopaniemi Statistical machine learning and.
Protein Quantitation II: Multiple Reaction Monitoring
NISS Metabolomics Workshop, Integrative Analysis of High Dimensional Gene Expression, Metabolite and Blood Chemistry Data Kwan R. Lee, Ph.D. and.
Improvements in Mass Spectrometry for Life Science Research – Does Agilent Have the Answer? Ashley Sage PhD.
Prof. Carolina Ruiz Computer Science Department Bioinformatics and Computational Biology Program WPI WELCOME TO BCB4003/CS4803 BCB503/CS583 BIOLOGICAL.
Bioinformatic Treatment of Human Metabolome Profile for Diagnostics Dr. Petr Lokhov & Dr. Alexander Archakov Institute of Biomedical Chemistry, RAMS.
S TRUCTURAL B IOINFORMATICS. A subset of Bioinformatics concerned with the of biological structures - proteins, DNA, RNA, ligands etc. It is the first.
Jeffery Loo NLM Associate Fellow ’03 – ’05 chemicalinformaticsforlibraries.
Metabolomics DNA RNA Protein Biochemicals (Metabolites) Genomics – 25,000 Genes Transcriptomics – 100,000 Transcripts Metabolomics – 2,800 Compounds Proteomics.
Mass Spectrometry. What are mass spectrometers? They are analytical tools used to measure the molecular weight of a sample. Accuracy – 0.01 % of the total.
Metabolomic Data Processing & Statistical Analysis
Proteomics Informatics Workshop Part III: Protein Quantitation
GTL User Facilities Facility II: Whole Proteome Analysis Michelle V. Buchanan.
Pharmacogenomics and personalized medicines Jean-Marie Boeynaems
Important Points in Drug Design based on Bioinformatics Tools History of Drug/Vaccine development –Plants or Natural Product Plant and Natural products.
Metabolomics 5/2/2014. ‘Omics Family Tree W. M. Claudino, et al., Journal of Clinical Oncology, 2007, 25(19), pp /2/2014.
Miniaturized Silicon Nanowire System for the In Vivo Diagnosis of Disease R. Myers, L. Rivera, Y. He, Z. Li and J. Villalba.
The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
2007 GeneSpring MS GeneSpring for Metabolite BioMarker Analysis using Mass Spectrometry data Agilent Q-TOF VIP Visit Jan 16-17, 2007 Santa Clara, CA Thon.
CS 790 – Bioinformatics Introduction and overview.
© 2010 SRI International - Company Confidential and Proprietary Information Quantitative Proteomics: Approaches and Current Capabilities Pathway Tools.
Finish up array applications Move on to proteomics Protein microarrays.
Metabolomics Metabolome Reflects the State of the Cell, Organ or Organism Change in the metabolome is a direct consequence of protein activity changes.
Mike Rusak and Laura Fairburn CURRENT OBSTACLES ON THE APPLICATION OF AMBIENT IONIZATION MS IN FORENSICS.
High throughput Protein Measurement Techniques Harin Kanani.
Proteomics Session 1 Introduction. Some basic concepts in biology and biochemistry.
Market Segment Training. AA ~$2,000M* GC ~$1,650M* Biotech ~$7,500M* Liquid ~$4,100M* (growth at ~6% per annum) *based on figures from SDI 2004 All prices.
Trend in diagnostic biochip development Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital.
Introduction to Biostatistics and Bioinformatics Experimental Design.
Nuclear Magnetic Resonance
Consumer Advocate Perspective Clinical Trials Registration Sharon F. Terry, JAM Sharon F. Terry, JAM President and CEO, Genetic Alliance, Inc. Founding.
Discovery of Therapeutics to Improve Quality of Life Ram Samudrala University of Washington.
Critical Path Initiative Sousan S. Altaie, Ph.D. Scientific Policy Advisor OIVD/CDRH.
Canadian Bioinformatics Workshops
Canadian Bioinformatics Workshops
What is proteomics? Richard Mbasu and Ben Richards.
Computational Challenges in Metabolomics (Part 1)
신기술 접목에 의한 신약개발의 발전전망과 전략 LGCI 생명과학 기술원. Confidential LGCI Life Science R&D 새 시대 – Post Genomic Era Genome count ‘The genomes of various species including.
RANIA MOHAMED EL-SHARKAWY Lecturer of clinical chemistry Medical Research Institute, Alexandria University MEDICAL RESEARCH INSTITUTE– ALEXANDRIA UNIVERSITY.
Methodological and Statistical Considerations in Clinical Research Dr. Gloria Crispino, CStat CMath Copy Rights; Do not reproduce without authorization.
Canadian Bioinformatics Workshops
Metabolomics Data Analysis
Biomedical Data Science for Precision Medicine
Introduction Results Aim of the study Methods Conclusion References
Optimizing Biological Data Integration
Mass Spectrometry Vs. Immunoassay
Metabolomics Study of Human Seminal Plasma of Infertile Men
Data Exchange & Public Reference Data
Data challenges in the pharmaceutical industry
Figure 1. Biotechnology sector’s knowledge base
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
Biotechnology Objectives: At the end of this lecture we will be able to identify and describe the uses of biotechnology in society.
Integrated Metabolomics Research Group, Korea Basic Science Institute
“Proteomics is a science that focuses on the study of proteins: their roles, their structures, their localization, their interactions, and other factors.”
Human Health and Disease
Multidimensional Drug Profiling By Automated Microscopy
Figure 2 Targeted versus untargeted metabolomics approaches
Proteomics Informatics David Fenyő
Biomedical Data Science for Precision Medicine
Benjamin Wooden, Nicolas Goossens, Yujin Hoshida, Scott L. Friedman 
Metabolomics: Preanalytical Variables
Standards Development for Metabolomics
The increasing availability of quantitative biological data from the human genome project, coupled with advances in instrumentation, reagents, methodologies,
Volume 25, Issue 3, Pages (March 2017)
Drug Design and Drug Discovery
Diagnostics and Prognostics
Proteomics Informatics David Fenyő
Global Discovery Chemistry, 11 August 2017
Presentation transcript:

Canadian Bioinformatics Workshops www.bioinformatics.ca

Module #: Title of Module 2

The Future of Metabolomics Module 7 The Future of Metabolomics David Wishart Informatics and Statistics for Metabolomics May 26-27, 2016

Metabolomics Is Growing Pubmed: Metabolomics OR Metabonomics OR Metabonome Year

But Where Is It Going? Year

Key Bottlenecks in Metabolomics Lack of automation Incomplete metabolome coverage Expensive/large equipment Lack of quantification Inability to translate findings to the clinic Making metabolomics matter to drug companies

Key Trends in Metabolomics Automated metabolomics Expanding metabolome coverage Making metabolomics portable Quantify, quantify, quantify… Moving metabolomics from the lab to the clinic Moving metabolomics (back) into drug development and discovery

Automated Metabolomics Bruker – Automated NMR Biocrates – Automated MS

Bayesil (Automated NMR) Uses probabilistic graphical models (PGM) – similar to HMMs Fits shift & peak intensity similar to the way humans perform fitting and pattern finding Requires prior knowledge of probable biofluid composition Fully automated phasing, referencing, water removal, baseline correction, peak convolution, identification and quantification Free web server http://bayesil.ca

GC-AutoFit (Automated GC-MS) Requires 3 spectra (sample, blank, alkane standards) Performs auto-alignment, peak ID, peak integration and concentration calculation Accepts NetCDF or mzXML files 60 sec per spectrum 45-70 cmpds ID’d and quantified, 96% accuracy Optimized for blood, urine, saliva and CSF Still requires careful sample preparation & derivatization http://gcms.wishartlab.com

Key Trends in Metabolomics Automated metabolomics Expanding metabolome coverage Making metabolomics portable Quantify, quantify, quantify… Moving metabolomics from the lab to the clinic Moving metabolomics (back) into drug development and discovery

Technology & Sensitivity Unknown unknowns 4 LC-MS or DI-MS 3 GC-MS TOF # Metabolites detected (Log10) 2 NMR 1 Known unknowns GC-MS Quad M mM M nM pM fM Sensitivity or LDL

What Are The Unknown Unknowns? Metabolites of Metabolites

The Food Metabolome Scalbert A. et al. (2014) Am. J. Clinical Nutr. 99(6):1286

Systematic Spectral Collection 100,000+ Compounds 800,000+ NMR, MS/MS Spectra $$

Systematic Spectral Prediction Predicts MS/MS spectra from known compounds via advanced machine learning techniques 50% more accurate than other systems Matches predicted MS/MS spectra (from HMDB, KEGG or user choice) to input MS/MS spectra Permits rapid compound ID from MS/MS spectra http://cfmid.wishartlab.com

Key Trends in Metabolomics Automated metabolomics Expanding metabolome coverage Making metabolomics portable Quantify, quantify, quantify… Moving metabolomics from the lab to the clinic Moving metabolomics (back) into drug development and discovery

Personalized Medical Monitoring Devices

Democratizing Metabolomics $10 million instrument, $200/test $1000 instrument, $2/test

Not As Absurd As You Think

Miniaturization via Microfluidics & Nanotech CE on a chip HPLC on a chip GC on a chip

E-Nose for Volatile Metabolites E-Nose uses 32 tiny sensors, which together are about the size of the nose on your face. They are connected to a small computer that takes the information from the sensors and figures out just what the smell is, similar to how your brain, through experience, learns to identify what your nose is smelling.

Protein and Aptamer-Mediated Metabolite Sensing + Metabolite “Open” form “Closed” form “Open” form “Closed” form Metabolite With GNP + SPR SERS Zimp

Working Prototype: Impedance-Based Metabolite Sensor iPhone App Developed by Dr. Jie Chen, University of Alberta

Key Trends in Metabolomics Automated metabolomics Expanding metabolome coverage Making metabolomics portable Quantify, quantify, quantify… Moving metabolomics from the lab to the clinic Moving metabolomics (back) into drug development and discovery

Quantification & Metabolomics >90% of published metabolomics studies are semi-quantitative (relative peak areas, intensities) <10% of published metabolomics studies use absolute quantification The field MUST become more quantitative if findings are to be translated to practical applications

Quantitative Metabolomics (Commercial) Chenomx– Automated NMR Bruker – Automated NMR Biocrates – Automated MS

Quantitative Metabolomics (Academic) Bayesil Batman GC-Autofit

Some Impressive Results… Human Biofluid Omics “Records” for Absolute Quantification Metabolomics Proteomics Genomics (Transcripts) Serum/Plasma 288 Identified & Quantified 1 73 Identified & Quantified 4 CSF 172 Identified & Quantified 2 130 Identified & Quantified 5 Urine 378 Identified & Quantified 3 63 Identified & Quantified 6 Psychogios N. et al. (2011) PLoS One 6(2): e16957 Mandal R. et al. (2012) Genome Med.;4(4):38. 3. Bouatra S. et al. (2013) PLoS One 8(9): e73076 4. MRM Proteomics Inc. (Victoria BC) reported in 2014 5. Percy AJ. et al. (2014) J. Proteome Res. (ePub Jun 9) 6. Chen YT. et al. (2012) J. Proteomics 75(12):3529

Key Trends in Metabolomics Automated metabolomics Expanding metabolome coverage Making metabolomics portable Quantify, quantify, quantify… Moving metabolomics from the lab to the clinic Moving metabolomics (back) into drug development and discovery

Some Grim Statistics Since 1970 > 700,000 biomarker papers published in PubMed Since 1970 <250 biomarkers have been approved for clinical use No markers approved (yet) using proteomics methods (lots use ELISA) 5 biomarker tests approved using transciptomics or gene chips

But Did You Know… Almost Everyone <25 Has Had A Metabolomic Test? Newborn Screening

“Omics” Testing Number of “approved” tests arising from Metabolomics/Clinical Chem. – 195 Number of “approved” tests arising from or using Genomics – 100-110 Number of “approved” single Protein tests (ELISA) – 60 Number of “approved” tests arising from or using Transcriptomics – 5 Number of “approved” tests arising from or using Proteomics - 0

How Does Metabolomics Do? (Prediction & Diagnosis)

Predicting Diseases

Diagnosing Diseases

Key Trends in Metabolomics Automated metabolomics Expanding metabolome coverage Making metabolomics portable Quantify, quantify, quantify… Moving metabolomics from the lab to the clinic Moving metabolomics (back) into drug development and discovery

Metabolomics & The Drug Industry $280 $60 $90 $250 $120 million 3.5 yrs 1 yr 2 yrs 3 yrs 2.5 yrs Discovery Phase I Phase II Phase III FDA Approval Drug Development Pipeline Chemistry Genomics Proteomics Metabolomics

Metabolomics in Drug Development Lead IND Synthesis Efficacy/In Vivo TOX P1 P2 P3 Efficacy/HTS Discovery Rapid Throughput Tox Screening Preclinical Safety Biomarkers and Mechanisms Preclinical Efficacy Biomarkers Clinical Safety Biomarkers PreLead Prioritization Clinical Efficacy Biomarkers

Applications in Patient Compliance (P2/P3 Trials) Ethanol!!

Applications in Drug Monitoring/Customization Drug Metabolite! Slow metabolizer Fast metabolizer

Traditional Drug Discovery

Metabolite-Based Drug Discovery

Metabolomics, CVD & Therapy Drug target Drug target Dietary target

Summary – The Future of Metabolomics Automated metabolomics Expanding metabolome coverage Making metabolomics portable Quantify, quantify, quantify… Moving metabolomics from the lab to the clinic Moving metabolomics (back) into drug development and discovery